Inbiomotion
4 known investors
Inbiomotion develops the MAF Test, a biomarker diagnostic based on MAF gene expression that helps doctors select early breast cancer patients for adjuvant bisphosphonate treatment. The test aims to identify MAF-negative patients who benefit from therapy while excluding MAF-positive patients who may not benefit or could be harmed.
BiotechDigital HealthMedical Devices
Investors · 4
In the news
Frequently asked questions
- What does Inbiomotion do?
- Inbiomotion develops the MAF Test, a biomarker diagnostic based on MAF gene expression that helps doctors select early breast cancer patients for adjuvant bisphosphonate treatment. The test aims to identify MAF-negative patients who benefit from therapy while excluding MAF-positive patients who may not benefit or could be harmed.
- Who are Inbiomotion's investors?
- Inbiomotion's investors include Criteria Bio Ventures, Ysios Capital, Alta Life Sciences, Asabys Partners.